Immunai to collaborate with Teva to enhance clinical decision making in immuno-oncology clinical trials

Karen Knudsen joins Paradigm Health’s board of directors as company prepares launch of AI-driven clinical trial data collection and management application

Paradigm Health announced on March 20 the appointment of Karen E. Knudsen to its board of directors, alongside the upcoming launch of its eSource clinical trial data application.

March 28, 2025

Vol.51 No.12

Clinical Roundup

Investigational Orca-T treatment for hematologic malignancies meets primary endpoint in phase III trial

Orca Bio, a late-stage biotechnology company, on March 17 announced results from the pivotal phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with acute myeloid leukemia, acute lymphoblastic leukemia, high-risk myelodysplastic syndrome and mixed-phenotype acute leukemia. Orca-T is manufactured using highly purified regulatory T-cells, hematopoietic stem cells and conventional T-cells derived from peripheral blood from either related or unrelated matched donors.

March 28, 2025

Vol.51 No.12

Clinical Roundup

Elahere shows survival benefit in long-term analysis for ovarian cancer patients in phase III study

AbbVie announced the final analysis of the confirmatory phase III MIRASOL trial evaluating the efficacy and safety of Elahere in women with folate receptor alpha-positive platinum-resistant ovarian cancer compared to chemotherapy.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Genmab’s Rina-S shows promise in treating advanced ovarian cancer

Genmab A/S announced on March 17 updated data from cohort B1 of the phase I/II RAINFOL-01 study of rinatabart sesutecan, an investigational folate receptor-alpha-targeted, TOPO1 antibody-drug conjugate that showed Rina-S 120 mg/m2 every three weeks resulted in a confirmed objective response rate of 55.6% (95% CI: 30.8-78.5) in heavily pre-treated ovarian cancer patients regardless of FRα expression levels.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Immunovia completes second clinical validation of next-gen pancreatic cancer test

Immunovia announced results from the VERIFI study, the second clinical validation study of its next-generation pancreatic cancer test.

March 21, 2025

Vol.51 No.11

In Brief

Jeffrey Rathmell named chair of the UChicago Ben May Department for Cancer Research, director of Ludwig Center for Metastasis Research

Jeffrey C. Rathmell, an immune and cancer cell metabolism researcher, was named chair of the Ben May Department for Cancer Research and director of the Ludwig Center for Metastasis Research at the University of Chicago, effective July 1.

March 07, 2025

Vol.51 No.09

Immunai to collaborate with Teva to enhance clinical decision making in immuno-oncology clinical trials

YOU MAY BE INTERESTED IN

Karen Knudsen joins Paradigm Health’s board of directors as company prepares launch of AI-driven clinical trial data collection and management application

Investigational Orca-T treatment for hematologic malignancies meets primary endpoint in phase III trial

Elahere shows survival benefit in long-term analysis for ovarian cancer patients in phase III study

Genmab’s Rina-S shows promise in treating advanced ovarian cancer

Immunovia completes second clinical validation of next-gen pancreatic cancer test

Jeffrey Rathmell named chair of the UChicago Ben May Department for Cancer Research, director of Ludwig Center for Metastasis Research

Renew today!

Subscriber content

Never miss an issue!

Login